Phenomix Sciences has announced the findings from new research conducted at Mayo Clinic and presented at ObesityWeek 2024, which demonstrates the utility of the MyPhenome test in predicting future weight gain. The study, ‘Gene Risk Score for Satiation Is Associated with Prospective Weight Gain’, showed participants with abnormal satiation and high gene risk scores (GRS) experienced 4% greater weight gain after five years.
The study was presented by Dr Diego Anazco, a research fellow at Mayo Clinic. In total, 71 were genotyped (68.9%). Most of the participants were females (n=76, 73.8%), 39.3±11.7 years and BMI of 32.4±4.7 kg/m2. There were no significant differences in baseline characteristics across groups except for a younger age for subjects with high CTS.
After five years of follow-up, those with high CTS had a larger increase in weight (10.4%±1.4) than those with low CTS (4.8%±0.9, p<0.001). Subjects with a high calories consumed to reach satiation GRS gained more weight (8.5%±1.6) than those with a low CTSGRS (4.7%±1.3, p<0.05).
These findings suggest the MyPhenome test's utility in identifying individuals at risk of progressive weight gain and highlighting a need for a targeted early intervention approach in obesity.
"With the continued groundbreaking research from our founders Dr Acosta and Dr Camilleri, we know more about the genetics of obesity than ever before," said Mark Bagnall, CEO of Phenomix Sciences. "For the first time, our company is looking beyond weight loss, and helping guide the industry toward early intervention and obesity screening. This approach has the potential to deliver significant economic and clinical benefits. These findings highlight the significant impact precision medicine is having in obesity treatment and we look forward to supporting continued research in this space."